Featured Press Releases

Thermo Fisher Scientific Introduces Innovative Mass Spectrometer to Advance Clinical Research

Thermo Fisher Scientific Introduces Innovative Mass Spectrometer to Advance Clinical Research

BioMarin to Present Data Showcasing VOXZOGO® (vosoritide)'s Impact on Bone Health and Quality of Life in Achondroplasia

BioMarin to Present Data Showcasing VOXZOGO® (vosoritide)'s Impact on Bone Health and Quality of Life in Achondroplasia

  • 17 Jun 2024

BioMarin Pharmaceutical Inc. announced the presentation of new data from an investigator-led...

CalciMedica Announces Positive Topline Data from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis

CalciMedica Announces Positive Topline Data from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis

SciTech Development reveals promising Phase 1A trial results for T-cell non-Hodgkin lymphoma therapy

SciTech Development reveals promising Phase 1A trial results for T-cell non-Hodgkin lymphoma therapy

ResQ Pharma receives PDUFA date for LipidRescue™, potentially the first FDA-approved treatment for Local Anesthetic Systemic Toxicity (LAST)

ResQ Pharma receives PDUFA date for LipidRescue™, potentially the first FDA-approved treatment for Local Anesthetic Systemic Toxicity (LAST)

Children’s Hospital Los Angeles completes its 100th retinal gene therapy procedure, advancing pediatric vision care.

Children’s Hospital Los Angeles completes its 100th retinal gene therapy procedure, advancing pediatric vision care.

Cellipont Bioservices and Secretome Therapeutics partner for cGMP manufacturing of the Master Cell Bank for their lead asset, STM-01

Cellipont Bioservices and Secretome Therapeutics partner for cGMP manufacturing of the Master Cell Bank for their lead asset, STM-01

  • Cellipont Bioservices
  • 22 Jan 2025
West introduces Daikyo PLASCAP® RUV closures in a new nested format at Pharmapack

West introduces Daikyo PLASCAP® RUV closures in a new nested format at Pharmapack

  • West Pharmaceutical Services, Inc.
  • 22 Jan 2025
Artax Biopharma validates AX-158, a first-in-class oral Nck modulator, in phase 2a for autoimmune disease

Artax Biopharma validates AX-158, a first-in-class oral Nck modulator, in phase 2a for autoimmune disease

  • Artax Biopharma
  • 21 Jan 2025
MalarVx licenses HDT Bio's repRNA/LION™ technology to develop a groundbreaking malaria vaccine

MalarVx licenses HDT Bio's repRNA/LION™ technology to develop a groundbreaking malaria vaccine

  • MalarVx, Inc.; HDT Bio Corp.
  • 20 Jan 2025
SeoulTech researchers unveil a novel approach to understanding PFOS-induced neurotoxicity, advancing environmental health studies

SeoulTech researchers unveil a novel approach to understanding PFOS-induced neurotoxicity, advancing environmental health studies

  • Seoul National University of Science and Technology
  • 19 Jan 2025
Chromatin Bioscience's synthetic promoter enables EsoBiotec's ESO-T01 CAR-T therapy to progress to clinical trials

Chromatin Bioscience's synthetic promoter enables EsoBiotec's ESO-T01 CAR-T therapy to progress to clinical trials

  • Chromatin Bioscience
  • 16 Jan 2025
The Precision Health Technologies Accelerator

Most Popular
January   2025
M T W T F S S
    1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31    

User Area

Discover

Engage with Us

© 2024 Pharmaceutical Era — A product of HISSM. All Rights Reserved.